Can Decentralized Trials Solve The Patient Diversity Problem?

Source: Clinical Leader

The COVID-19 pandemic in 2020 quickly changed how clinical trials are conducted. Many companies suddenly needed to switch to decentralized trial models to protect their studies and the safety of participants. Now the main question being asked is where do clinical trials go from here and what can we expect in 2021? And what does the future hold for emerging technologies, virtual trials, and patient centricity in the age of COVID?

In this webinar segment, Michelle Longmire of Medable and Jeff Kasher of Patients Can’t Wait discuss how a decentralized clinical trial model might enable greater patient diversity in studies. Debbie Profit of Otsuka also looks at how companies should prepare for onsite FDA inspections during COVID. 

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader